ATE528002T1 - Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden - Google Patents

Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden

Info

Publication number
ATE528002T1
ATE528002T1 AT07861312T AT07861312T ATE528002T1 AT E528002 T1 ATE528002 T1 AT E528002T1 AT 07861312 T AT07861312 T AT 07861312T AT 07861312 T AT07861312 T AT 07861312T AT E528002 T1 ATE528002 T1 AT E528002T1
Authority
AT
Austria
Prior art keywords
angiogenesis
hyperproliferative
treatment
mediated diseases
carboxamide derivatives
Prior art date
Application number
AT07861312T
Other languages
English (en)
Inventor
Stephen Boyer
David Cantin
Sidney X Liang
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ATE528002T1 publication Critical patent/ATE528002T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT07861312T 2006-05-19 2007-05-18 Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden ATE528002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80170006P 2006-05-19 2006-05-19
PCT/US2007/011981 WO2008048375A1 (en) 2006-05-19 2007-05-18 Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders

Publications (1)

Publication Number Publication Date
ATE528002T1 true ATE528002T1 (de) 2011-10-15

Family

ID=39314319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07861312T ATE528002T1 (de) 2006-05-19 2007-05-18 Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden

Country Status (6)

Country Link
US (1) US20090306103A1 (de)
EP (1) EP2023926B1 (de)
JP (1) JP2009537632A (de)
AT (1) ATE528002T1 (de)
CA (1) CA2652417A1 (de)
WO (1) WO2008048375A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
RU2011142597A (ru) * 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. Производные сложных эфиров аминокислот, их соли и способы применения
KR101106050B1 (ko) 2009-03-25 2012-01-18 한국과학기술연구원 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
SG190735A1 (en) 2011-02-28 2013-07-31 Calitor Sciences Llc Substituted quinoline compounds and methods of use
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
CN107245071A (zh) 2013-04-09 2017-10-13 广州慧柏瑞生物医药科技有限公司 抗新生血管的化合物、其中间体及其用途
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN106573915B (zh) 2014-08-01 2020-12-25 纽韦卢森公司 针对布罗莫结构域有活性的化合物
JP6708130B2 (ja) * 2014-12-25 2020-06-10 小野薬品工業株式会社 キノリン誘導体
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
LT3436461T (lt) 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
CN106735289B (zh) * 2016-11-30 2018-09-04 燕山大学 一种以醋酸奥曲肽为模板制备立方体状银纳米盒的方法
CN106735288B (zh) * 2016-11-30 2018-12-28 燕山大学 一种以醋酸伐普肽为生物模板制备银纳米球壳的方法
CN106694901B (zh) * 2016-12-27 2018-12-28 燕山大学 一种基于醋酸伐普肽制备银金合金纳米球壳
CN119707932A (zh) 2017-01-26 2025-03-28 小野药品工业株式会社 喹啉衍生物的乙磺酸盐
CN111386273B (zh) 2017-09-27 2024-06-14 因赛特公司 可用作tam抑制剂的吡咯并三嗪衍生物的盐
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN113164398B (zh) 2018-06-29 2023-11-03 因赛特公司 Axl/mer抑制剂的制剂
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CN114787144A (zh) * 2019-09-26 2022-07-22 埃克塞里艾克西斯公司 吡啶酮化合物及用于调节蛋白激酶的方法
KR20210100557A (ko) * 2020-02-06 2021-08-17 웰마커바이오 주식회사 Kras 돌연변이와 관련된 암의 예방 또는 치료용 약학 조성물
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
US20230293454A1 (en) * 2020-08-07 2023-09-21 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome and pegaspargase
WO2022237843A1 (zh) * 2021-05-12 2022-11-17 微境生物医药科技(上海)有限公司 Axl抑制剂
WO2025096463A1 (en) * 2023-10-30 2025-05-08 Vibliome Therapeutics, Llc Plk4 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors

Also Published As

Publication number Publication date
JP2009537632A (ja) 2009-10-29
CA2652417A1 (en) 2008-04-24
EP2023926A4 (de) 2010-08-04
EP2023926B1 (de) 2011-10-12
US20090306103A1 (en) 2009-12-10
WO2008048375A1 (en) 2008-04-24
EP2023926A1 (de) 2009-02-18

Similar Documents

Publication Publication Date Title
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
ZA200907137B (en) Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
EP2059282A4 (de) Vorrichtung, verfahren und geräte zur behandlung von augenerkrankungen
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP2046315A4 (de) Therapeutische mittel zur behandlung maligner lymphome
ATE453642T1 (de) Substituierte phenylaminopyrimidine
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
EP2323649A4 (de) Behandlung verschiedener leiden mit 7,8-dihydroxyflavon und derivaten davon
WO2010121225A3 (en) Method of treating disorders associated with protein kinase ck2 activity
GEP20156224B (en) Therapeutic agent for mood disorders
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
MX2013010025A (es) (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties